ข่าวประชาสัมพันธ์ Acute Coronary Syndrome+Daiichi Sankyo Company

U.S. Regulators Approve Prasugrel for Reduction of Cardiovascular Events In Patients with Acute Coronary Syndromes Managed with Artery-Opening Procedure

Daiichi Sankyo Company, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Effient(TM) (prasugrel) tablets for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI). PCI usually includes the placement of a stent to help keep the artery open. Prasugrel works by

13 กรกฎาคม 2552 09:35 น.

European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI

Heart patients with acute coronary syndrome (ACS) undergoing an artery-opening procedure will soon have a new treatment option to help prevent heart attacks. Daiichi Sankyo Company, Limited ... ก.พ. 52

CMC Biologics Announces Agreement With Daiichi Sankyo Company to Develop and Manufacture Antibodies

CMC Biologics today announced the execution of an agreement with Daiichi Sankyo Co., Ltd. ('Daiichi Sankyo') to provide process development support and manufacture of several clinical-stage antibodies... ต.ค. 54

New ESC Guidelines Recommend Efient(R) (Prasugrel) as First-line Antiplatelet Therapy for Patients with Non-ST Segment Myocardial Infarction and Unstable Angina Acute Coronary Syndromes

In new guidelines from the European Society of Cardiology (ESC), prasugrel a once daily oral antiplatelet medicine... ก.ย. 54

New ESC Guidelines Recommend BRILIQUE (ticagrelor) in all Moderate-To-High Risk Patients With Non-ST Elevation Acute Coronary Syndromes

- This release is not intended for US media Ticagrelor Recommended for Medically & Invasively Managed NSTE-ACS Patients Regardless of Prior Treatment with... ส.ค. 54

Phase II Study Showed Switching ACS-PCI Patients on Maintenance Clopidogrel/Aspirin to Prasugrel/Aspirin Reduced Maximal Platelet Aggregation After One Week

In a Phase II study, Acute Coronary Syndrome (ACS) patients on maintenance clopidogrel/aspirin therapy who were switched to prasugrel (Efient(R)... ก.ย. 53

Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes

- SEPIA-ACS Multiple-dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The... ส.ค. 52

ภาควิชาอายุรศาสตร์และสาขาวิชาหทัยวิทยา คณะแพทยศาสตร์ศิริราชพยาบาล Cardiac Biomarkers in Acute Coronary Syndrome: Emphasizing High Sensitive Troponin

ภาควิชาอายุรศาสตร์และสาขาวิชาหทัยวิทยา คณะแพทยศาสตร์ศิริราชพยาบาล จัดบรรยายวิชาการเรื่อง Cardiac Biomarkers in Acute Coronary Syndrome: Emphasizing high... ส.ค. 52

World Heart Federation, Daiichi Sankyo and Lilly Partner to Improve Cardiovascular Health

The World Heart Federation, Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) announced today that they have partnered to improve cardiovascular health internationally. The... มี.ค. 52

Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee

The U.S. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee voted 9 to 0 that prasugrel, an investigational antiplatelet agent, should be approved for the treatment of patients with acute... ก.พ. 52

สรุปข่าวเอเชียเน็ทประจำวันพฤหัสบดีที่ 17 กรกฎาคม 2551

ข้อตกลง โตเกียวและนิวเดลี: หลังจากที่มีการคาดการณ์กันมากในส่วนของสื่อมวลชนและตลาดหุ้น ไดอิจิ ซังเคียว จำกัด (Daiichi Sankyo Company, Limited) และ แรนแบ็กซี่ ลาบอราทอรีส์ จำกัด (Ranbaxy Laboratories Limited) ได้ตอกย้ำถึงข้อตกลงระหว่างกัน ... ก.ค. 51

AsiaNet Daily Summary - Press Releases for Thursday, July 17, 2008

BINDING DEAL... TOKYO and NEW DELHI: Following intense speculation in sections of the media and the stock market, Daiichi Sankyo Company, Limited and Ranbaxy Laboratories Limited reiterate that the agreement between Daiichi Sankyo,... ก.ค. 51

แรนแบ็กซี่ เตรียมดึง ไดอิจิ ซังเคียว เข้าถือหุ้นใหญ่ในบริษัท หวังขึ้นแท่นบริษัทเวชภัณฑ์ยักษ์ใหญ่ของโลก

บริษัท ไดอิจิ ซังเคียว จำกัด (Daiichi Sankyo Company, Limited) (TSE: 4568.JP) บริษัทเวชภัณฑ์รายใหญ่ที่สุดแห่งหนึ่งของญี่ปุ่น และ แรนแบ็กซี่ ลาบอราทอรีส์ จำกัด (Ranbaxy Laboratories Limited) (NSE/BSE... มิ.ย. 51

Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse

Daiichi Sankyo Company, Limited (TSE: 4568.JP) ("Daiichi Sankyo"), one of the largest pharmaceutical companies in Japan, and Ranbaxy Laboratories Limited (NSE/BSE: Ranbaxy... มิ.ย. 51

New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)

- A new Step Forward may Help Increase Appropriate Early use of Plavix(R) by Simplifying Administration in Acute Coronary Syndrome Patients Sanofi-aventis (EURONEXT: SAN and... มี.ค. 51

New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering from Acute Coronary Syndrome

sanofi-aventis announced today that one year findings from the landmark ExTRACT-TIMI 25 and STEEPLE studies confirm clear net clinical benefit for patients with acute ST... ก.ย. 50